company background image
BIOC

Biocept NasdaqCM:BIOC Stock Report

Last Price

US$1.42

Market Cap

US$26.0m

7D

-7.8%

1Y

-68.7%

Updated

18 May, 2022

Data

Company Financials +
BIOC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BIOC Stock Overview

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample.

Biocept Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biocept
Historical stock prices
Current Share PriceUS$1.42
52 Week HighUS$4.97
52 Week LowUS$1.40
Beta0.66
1 Month Change-21.55%
3 Month Change-44.31%
1 Year Change-68.65%
3 Year Change-89.08%
5 Year Change-99.68%
Change since IPO-99.98%

Recent News & Updates

Shareholder Returns

BIOCUS BiotechsUS Market
7D-7.8%5.7%0.5%
1Y-68.7%-21.4%-11.5%

Return vs Industry: BIOC underperformed the US Biotechs industry which returned -19.5% over the past year.

Return vs Market: BIOC underperformed the US Market which returned -8.1% over the past year.

Price Volatility

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Average Weekly Movement8.5%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: BIOC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BIOC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997179Sam Riccitellihttps://biocept.com

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.

Biocept Fundamentals Summary

How do Biocept's earnings and revenue compare to its market cap?
BIOC fundamental statistics
Market CapUS$26.03m
Earnings (TTM)-US$2.82m
Revenue (TTM)US$61.25m

0.4x

P/S Ratio

-8.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOC income statement (TTM)
RevenueUS$61.25m
Cost of RevenueUS$37.76m
Gross ProfitUS$23.49m
Other ExpensesUS$26.31m
Earnings-US$2.82m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.17
Gross Margin38.34%
Net Profit Margin-4.61%
Debt/Equity Ratio0%

How did BIOC perform over the long term?

See historical performance and comparison

Valuation

Is Biocept undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: BIOC ($1.42) is trading below our estimate of fair value ($9.16)

Significantly Below Fair Value: BIOC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BIOC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BIOC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIOC is good value based on its PB Ratio (0.6x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOC's revenue (9.3% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: BIOC's revenue (9.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Biocept performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


14.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIOC is currently unprofitable.

Growing Profit Margin: BIOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIOC is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.

Accelerating Growth: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BIOC has a negative Return on Equity (-7.53%), as it is currently unprofitable.


Financial Health

How is Biocept's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BIOC's short term assets ($45.7M) exceed its short term liabilities ($11.8M).

Long Term Liabilities: BIOC's short term assets ($45.7M) exceed its long term liabilities ($11.2M).


Debt to Equity History and Analysis

Debt Level: BIOC is debt free.

Reducing Debt: BIOC has no debt compared to 5 years ago when its debt to equity ratio was 407.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BIOC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BIOC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.3% per year.


Dividend

What is Biocept current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIOC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Sam Riccitelli (62 yo)

0.25

Tenure

US$103,041

Compensation

Mr. Samuel D. Riccitelli, also known as Sam, serves as Independent Director at Biocept, Inc. since October 21, 2020 and Independent Chairman since July 2021. Mr. Riccitelli serves as Interim President and...


Leadership Team

Experienced Management: BIOC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: BIOC's board of directors are seasoned and experienced ( 11.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.1%.


Top Shareholders

Company Information

Biocept, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biocept, Inc.
  • Ticker: BIOC
  • Exchange: NasdaqCM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$26.032m
  • Shares outstanding: 16.90m
  • Website: https://biocept.com

Number of Employees


Location

  • Biocept, Inc.
  • 9955 Mesa Rim Road
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.